The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Systematic identification of genomic markers of drug sensitivity in cancer cells
Open accessAbstract
Clinical responses to anticancer therapies are often restricted to a subset of patients. In some cases, mutated cancer genes are potent biomarkers for responses to targeted agents. Here, to uncover new biomarkers of sensitivity and resistance to cancer therapeutics, we screened a panel of several hundred cancer cell lines--which represent much of the tissue-type and genetic diversity of human cancers--with 130 drugs under clinical and preclinical investigation. In aggregate, we found that mutated cancer genes were associated with cellular response to most currently available cancer drugs. Classic oncogene addiction paradigms were modified by additional tissue-specific or expression biomarkers, and some frequently mutated genes were associated with sensitivity to a broad range of therapeutic agents. Unexpected relationships were revealed, including the marked sensitivity of Ewing's sarcoma cells harbouring the EWS (also known as EWSR1)-FLI1 gene translocation to poly(ADP-ribose) polymerase (PARP) inhibitors. By linking drug activity to the functional complexity of cancer genomes, systematic pharmacogenomic profiling in cancer cell lines provides a powerful biomarker discovery platform to guide rational cancer therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Large-scale efforts aimed at linking tumor genomic alterations with sensitivity to cytotoxic and targeted therapies have uncovered a wealth of pharmacogenomic interactions in NSCLC and other cancer types149–152.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [150]
In the citing paper
“BRAF mutation was associated with nutlin 3a sensitivity in the same study130.”
From MDM2, MDMX and p53 in oncogenesis and cancer therapy (2013) · cites this paper as [130]
In the citing paper
“p53 mutation status was the strongest indicator of nutlin 3a resistance”
From MDM2, MDMX and p53 in oncogenesis and cancer therapy (2013) · cites this paper as [130]
In the citing paper
“Even with such a simple readout, genes and pathways that determine drug response can be identified,199,200”
From Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence (2023) · cites this paper as [199]
In the citing paper
“More than 1200 established cancer cell lines and newly derived organoid models comprise the foundational model set of the Passports, including all those utilized in the Sanger’s GDSC project (5, 18) as well as cell models generated as part of the Human Cancer Models Initiative.”
From Cell Model Passports-a hub for clinical, genetic and functional datasets of preclinical cancer models (2019) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cytoscape: A software Environment for integrated models of biomolecular interaction networks
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888
Regularization and Variable Selection Via the Elastic Net
Zou, H., & Hastie, T. (2005) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.1467-9868.2005.00503.x · Cited by 20,957
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Self-citationBolstad, B. M., Irizarry, R. A., Åstrand, M., & Speed, T. P. (2003) · Bioinformatics · doi:10.1093/bioinformatics/19.2.185 · Cited by 8,328
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Clustering by Passing Messages Between Data Points
Frey, B. J., & Dueck, D. (2007) · Science · doi:10.1126/science.1136800 · Cited by 6,855
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477
Self-citationBoland, C. R., Thibodeau, S. N., Hamilton, S. R., Sidransky, D., Eshleman, J. R., Burt, R. W., Meltzer, S. J., Rodrı́guez-Bigas, M. A., Fodde, R., Ranzani, G. N., et al. (1998) · PubMed · Cited by 4,087
Flagged first, then by citations
Cited by
Sorted by citations
Items 801–900 of 1,004
Quartararo, C. E., Reznik, E., deCarvalho, A. C., Mikkelsen, T., & Stockwell, B. R. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00128 · Cited by 40
Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders
Schadt, E. E., Buchanan, S., Brennand, K. J., & Merchant, K. M. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00252 · Cited by 39
Identifying the determinants of response to MDM2 inhibition
Saiki, A. Y., Caenepeel, S. R., Cosgrove, E. J., Su, C., Boedigheimer, M. J., & Oliner, J. D. (2015) · Oncotarget · doi:10.18632/oncotarget.3116 · Cited by 39
Vural, S., Palmisano, A., Reinhold, W. C., Pommier, Y. G., Teicher, B. A., & Krushkal, J. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01026-4 · Cited by 41
Sharifi-Noghabi, H., Harjandi, P. A., Zolotareva, O. I., Collins, C. C., & Ester, M. (2021) · Nature Machine Intelligence · doi:10.1038/s42256-021-00408-w · Cited by 39
Winsorization for Robust Bayesian Neural Networks
Sharma, S., & Chatterjee, S. (2021) · Entropy · doi:10.3390/e23111546 · Cited by 49
Self-citationComputation as the Mechanistic Bridge Between Precision Medicine and Systems Therapeutics
Hansen, J., & Iyengar, R. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.199 · Cited by 40
Synthetic Lethal Vulnerabilities of Cancer
de la Cruz, F. F., Gapp, B. V., & Nijman, S. M. B. (2014) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124511 · Cited by 43
Mpindi, J.-P., Potdar, S., Bychkov, D., Saarela, J., Saeed, K., Wennerberg, K., Aittokallio, T. A., Östling, P., & Kallioniemi, O. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv455 · Cited by 39
Bonsang‐Kitzis, H., Sadacca, B., Hamy, A., Moarii, M., Pinheiro, A., Laurent, C., & Reyal, F. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1061176 · Cited by 40
Foy, J., Tortereau, A., Caulı́n, C., Texier, V. L., Lavergne, E., Thomas, E., Chabaud, S., Pérol, D., Lachuer, J., Lang, W., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8321 · Cited by 41
Zhao, P., Chen, H., Wen, D., Mou, S., Zhang, F., & Zheng, S. (2018) · 癌症：英文版 · doi:10.1186/s40880-018-0323-y · Cited by 37
A quantile regression forest based method to predict drug response and assess prediction reliability
Fang, Y., Xu, P., Yang, J., & Qin, Y. (2018) · PLoS ONE · doi:10.1371/journal.pone.0205155 · Cited by 39
The genomic landscape of UM-SCC oral cavity squamous cell carcinoma cell lines
Ludwig, M., Kulkarni, A., Birkeland, A. C., Michmerhuizen, N. L., Foltin, S. K., Mann, J. E., Hoesli, R. C., Devenport, S. N., Jewell, B. M., Shuman, A. G., et al. (2018) · Oral Oncology · doi:10.1016/j.oraloncology.2018.10.031 · Cited by 39
Genomic characterization of cervical cancer based on human papillomavirus status
Zhang, L., Jiang, Y., Lu, X., Zhao, H., Chen, C., Wang, Y., Hu, W., Zhu, Y., Yan, H., & Yan, F. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.12.017 · Cited by 39
USP19 deubiquitinates EWS-FLI1 to regulate Ewing sarcoma growth
Gierisch, M. E., Pedot, G., Walser, F., Lopez-Garcia, L. A., Jaaks, P., Niggli, F. K., & Schäfer, B. W. (2019) · Scientific Reports · doi:10.1038/s41598-018-37264-5 · Cited by 43
Drenberg, C. D., Shelat, A. A., Dang, J., Cotton, A., Orwick, S. J., Li, M., Jeon, J. Y., Fu, Q., Buelow, D. R., Pioso, M. S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09917-0 · Cited by 39
Discovering long noncoding RNA predictors of anticancer drug sensitivity beyond protein-coding genes
Nath, A., Lau, E. Y.-T., Lee, A. M., Geeleher, P., Cho, W. C. S., & Huang, R. S. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1909998116 · Cited by 40
Gupta, A., Gautam, P., Wennerberg, K., & Aittokallio, T. A. (2020) · Communications Biology · doi:10.1038/s42003-020-0765-z · Cited by 35
TDP1 and PARP1 Deficiency Are Cytotoxic to Rhabdomyosarcoma Cells
Fam, H. K., Walton, C., Mitra, S. A., Chowdhury, M. K., Osborne, N., Choi, K., Sun, G., Wong, P. C. W., O’Sullivan, M. J., Turashvili, G., et al. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0575 · Cited by 39
HER2-mTOR signaling–driven breast cancer cells require ER-associated degradation to survive
Singh, N., Joshi, R., & Komurov, K. (2015) · Science Signaling · doi:10.1126/scisignal.aaa6922 · Cited by 39
Biomarker-driven patient selection for early clinical trials
Dienstmann, R., Rodon, J. A., & Tabernero, J. M. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32835ff3cb · Cited by 40
Epigenetic profiling joins personalized cancer medicine
Heyn, H., Méndez‐González, J., & Esteller, M. (2013) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.13.36 · Cited by 39
Huehls, A. M., Wagner, J. M., Huntoon, C. J., & Karnitz, L. M. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.080614 · Cited by 37
Comparison of two endogenous delivery agents in cancer therapy: Exosomes and ferritin
Li, L., Zhang, L., & Knez, M. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.05.006 · Cited by 40
Henry, R. E., Barry, E., Castriotta, L., Ladd, B., Markovets, A. A., Beran, G. J., Ren, Y., Zhou, F., Adam, A., Zinda, M. J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10859 · Cited by 39
Wang, Y., Fang, J., & Chen, S. (2016) · Scientific Reports · doi:10.1038/srep32679 · Cited by 37
Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition
Mateo, F., Arenas, E. J., Aguilar, H., Serra-Musach, J., de Garibay, G. R., Boni, J., Maicas, M., Du, S., Iorio, F., Herranz, C., et al. (2016) · Oncogene · doi:10.1038/onc.2016.427 · Cited by 37
Self-citationCanlı, S. D., Gömceli, İ., İşbilen, M., Dayanç, B. E., Tez, M., Bostancı, E. B., Turhan, N., Akoğlu, M., Ozyerli‐Goknar, E., Durdu, S., et al. (2017) · Journal of Cancer · doi:10.7150/jca.17872 · Cited by 38
Oskooei, A., Manica, M., Mathis, R., & Martínez, M. R. (2019) · Scientific Reports · doi:10.1038/s41598-019-52093-w · Cited by 44
Güllüoğlu, Ş., Tüysüz, E. C., Şahin, M., Kuşkucu, A., Yaltırık, C. K., Türe, U., Küçükkaraduman, B., Akbar, M. W., Gure, A. O., Bayrak, Ö. F., et al. (2018) · Brain Research · doi:10.1016/j.brainres.2018.08.035 · Cited by 40
The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity
Heisey, D. A. R., Lochmann, T. L., Floros, K. V., Coon, C. M., Powell, K. M., Jacob, S., Calbert, M. L., Ghotra, M. S., Stein, G. T., Maves, Y. K., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0277 · Cited by 35
Self-citationJoshi, R. S., de Moura, M. C., Piñeyro, D., Álvarez‐Errico, D., Arribas, C., & Esteller, M. (2020) · Epigenetics · doi:10.1080/15592294.2020.1762398 · Cited by 39
Homologous recombination repair deficiency as a therapeutic target in sarcoma
Oza, J. H., Doshi, S. D., Hao, L. Y., Musi, E., Schwartz, G. K., & Ingham, M. A. (2020) · Seminars in Oncology · doi:10.1053/j.seminoncol.2020.10.002 · Cited by 39
Izar, B., Rotow, J. K., Gainor, J. F., Clark, J. W., & Chabner, B. A. (2013) · Pharmacological Reviews · doi:10.1124/pr.113.007807 · Cited by 38
In Vivo Modeling of Human Breast Cancer Using Cell Line and Patient-Derived Xenografts
Souto, E. P., Dobrolecki, L. E., Villanueva, H. J., Sikora, A. G., & Lewis, M. T. (2022) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-022-09520-y · Cited by 38
van Pel, D. M., Stirling, P. C., Minaker, S. W., Sipahimalani, P., & Hieter, P. (2013) · G3 Genes Genomes Genetics · doi:10.1534/g3.112.004754 · Cited by 39
Vuong, H., Cheng, F., Lin, C.-C., & Zhao, Z. (2014) · Genome Medicine · doi:10.1186/preaccept-9791347081401328 · Cited by 37
A BRCA1 deficient, NFκB driven immune signal predicts good outcome in triple negative breast cancer
Buckley, N. E., Haddock, P., Simoes, R. D. M., Parkes, E. E., Irwin, G. W., Emmert‐Streib, F., McQuaid, S., Kennedy, R. D., & Mullan, P. B. (2016) · Oncotarget · doi:10.18632/oncotarget.7865 · Cited by 36
DNA Methylation and Chromatin Remodeling: The Blueprint of Cancer Epigenetics
Bhattacharjee, D., Shenoy, S., & Bairy, L. K. (2016) · Scientifica · doi:10.1155/2016/6072357 · Cited by 37
Amzallag, A., Ramaswamy, S., & Benes, C. H. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-2642-7 · Cited by 37
Self-citationP16 methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib
Li, P., Zhang, X., Gu, L., Zhou, J., & Deng, D. (2019) · PLoS ONE · doi:10.1371/journal.pone.0223084 · Cited by 38
Palve, V. C., Knezevic, C. E., Bejan, D. S., Luo, Y., Li, X., Novakova, S., Welsh, E. A., Fang, B., Kinose, F., Haura, E. B., et al. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.07.008 · Cited by 37
Artificial Intelligence, Machine Learning, and Deep Learning in Real-Life Drug Design Cases
Müller, C., Rabal, O., & Gonzalez, C. D. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1787-8_16 · Cited by 38
One oncogene, several vulnerabilities: EWS/FLI targeted therapies for Ewing sarcoma
Flores, G., & Grohar, P. J. (2021) · Journal of bone oncology · doi:10.1016/j.jbo.2021.100404 · Cited by 39
Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma
Lue, H.-W., Cole, B. C., Rao, S. A. M., Podolak, J., Gaest, A. V., King, C. J., Eide, C. A., Wilmot, B., Xue, C., Spellman, P. T., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5971 · Cited by 37
Stirnweiß, A., Oommen, J., Kotecha, R. S., Kees, U. R., & Beesley, A. H. (2017) · Oncotarget · doi:10.18632/oncotarget.22862 · Cited by 37
The transcriptional landscape of glycosylation-related genes in cancer
Rodríguez, E., Lindijer, D., van Vliet, S. J., García-Vallejo, J. J., & van Kooyk, Y. (2024) · iScience · doi:10.1016/j.isci.2024.109037 · Cited by 36
Synthetic lethality and cancer: cohesin and PARP at the replication fork
O’Neil, N. J., van Pel, D. M., & Hieter, P. (2013) · Trends in Genetics · doi:10.1016/j.tig.2012.12.004 · Cited by 42
Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer
Cirone, P., Andresen, C. J., Eswaraka, J. R., Lappin, P. B., & Bagi, C. M. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2376-1 · Cited by 37
Liu, Q., Wang, M., Kern, A. M., Khaled, S., Han, J., Yeap, B. Y., Hong, T. S., Settleman, J., Benes, C. H., Held, K. D., et al. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0570 · Cited by 36
Self-citationCrafter, C., VINCENT, J. P., TANG, E. K. Y., Dudley, P., James, N. H., Klinowska, T. C. M., & Davies, B. R. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3062 · Cited by 36
Cyclotherapy: opening a therapeutic window in cancer treatment
van Leeuwen, I. M. M. (2012) · Oncotarget · doi:10.18632/oncotarget.524 · Cited by 36
Li, X., Cai, H., Zheng, W., Tong, M., Li, H., Ao, L., Li, J., Hong, G., Li, M., Guan, Q., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7087 · Cited by 35
Use of big data in drug development for precision medicine
Kim, R. S., Goossens, N., & Hoshida, Y. (2016) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2016.1174062 · Cited by 36
Hanigan, T. W., Aboukhatwa, S. M., Taha, T. Y., Frasor, J. M., & Petukhov, P. A. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.08.015 · Cited by 36
Fujita, N., Mizuarai, S., Murakami, K., & Nakai, K. (2018) · Scientific Reports · doi:10.1038/s41598-018-28066-w · Cited by 37
More than fishing for a cure: The promises and pitfalls of high throughput cancer cell line screens
Ling, A. L., Gruener, R. F., Fessler, J. L., & Huang, R. S. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.06.014 · Cited by 35
Su, D., Zhang, D., Jin, J., Ying, L., Han, M., Chen, K., Li, B., Wu, J., Xie, Z., Zhang, F., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12846-7 · Cited by 37
Self-citationCifola, I., Pietrelli, A., Consolandi, C., Severgnini, M., Mangano, E., Russo, V. E. A., Bellis, G. D., & Battaglia, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063597 · Cited by 41
Microfluidic Biopsy Trapping Device for the Real-Time Monitoring of Tumor Microenvironment
Holton, A. B., Sinatra, F. L., Kreahling, J., Conway, A. J., Landis, D. A., & Altiok, S. (2017) · PLOS ONE · doi:10.1371/journal.pone.0169797 · Cited by 35
Gene Expression Profiles in Cancers and Their Therapeutic Implications
Creighton, C. J. (2023) · The Cancer Journal · doi:10.1097/ppo.0000000000000638 · Cited by 35
Li, Y., Xu, R., Wu, Y., Guo, J., Quan, F., Pei, Y., Huang, D., Zhao, X. R., Gao, H., Liu, J., et al. (2023) · Science Advances · doi:10.1126/sciadv.adi1965 · Cited by 35
Justus, C. R., Sanderlin, E. J., Dong, L., Sun, T., Chi, J., Lertpiriyapong, K., & Yang, L. V. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1305-6 · Cited by 36
Qu, X., Li, M., Zhang, H., Lin, C., Wang, F., Xiao, M., Zhou, Y., Shi, J., Aldalbahi, A. K., Pei, H., et al. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b10116 · Cited by 34
Drug response prediction by ensemble learning and drug-induced gene expression signatures
Tan, M., Özgül, O. F., Bardak, B., Ekşioğlu, I., & Sabuncuoğlu, S. (2018) · Genomics · doi:10.1016/j.ygeno.2018.07.002 · Cited by 35
Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer
Liu, Y., Xu, H., der Jeught, K. V., Li, Y., Liu, S., Zhang, L., Fang, Y., Zhang, X., Radovich, M., Schneider, B. P., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci98727 · Cited by 38
RetractedKnowledge-guided gene prioritization reveals new insights into the mechanisms of chemoresistance
Emad, A., Cairns, J., Kalari, K. R., Wang, L., & Sinha, S. (2017) · Genome biology · doi:10.1186/s13059-017-1282-3 · Cited by 33
White, B. S., Khan, S. A., Mason, M. J., Ammad-ud-din, M., Potdar, S., Malani, D., Kuusanmäki, H. A., Druker, B. J., Heckman, C. A., Kallioniemi, O., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00209-9 · Cited by 33
Novel approaches to improving the chemical safety of the meat chain towards toxicants
Engel, E., Ratel, J., Bouhlel, J., Planche, C., & Meurillon, M. (2015) · Meat Science · doi:10.1016/j.meatsci.2015.05.016 · Cited by 35
Gross, S. M., Dane, M. A., Smith, R. L., Devlin, K. L., McLean, I. C., Derrick, D. S., Mills, C. E., Subramanian, K., London, A. B., Torre, D., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03975-9 · Cited by 29
Verhagen, H. J. M. P., de Leeuw, D. C., Roemer, M. G. M., Denkers, F., Pouwels, W., Rutten, A. P., Celie, P. H. N., Ossenkoppele, G. J., Schuurhuis, G. J., & Smit, L. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.268 · Cited by 36
The opportunities of mining historical and collective data in drug discovery
Wassermann, A. M., Lounkine, E., Davies, J. W., Glick, M., & Camargo, L. M. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2014.11.004 · Cited by 34
Developmental origins shape the paediatric cancer genome
Chen, X., Yang, W., Roberts, C. W. M., & Zhang, J. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00684-9 · Cited by 49
Self-citationGenetic mutations in human rectal cancers detected by targeted sequencing
Bai, J., Gao, J., Mao, Z., Wang, J., Li, J., Li, W., Lei, Y., Li, S., Wu, Z., Tang, C., et al. (2015) · Journal of Human Genetics · doi:10.1038/jhg.2015.71 · Cited by 33
Quantitative high-throughput screening data analysis: challenges and recent advances
Shockley, K. R. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.10.005 · Cited by 36
Gustafsson, M., Edström, M., Gawel, D. R., Nestor, C. E., Wang, H., Zhang, H., Barrenäs, F., Tojo, J., Kockum, I. S., Olsson, T. P., et al. (2014) · Genome Medicine · doi:10.1186/gm534 · Cited by 33
Cortés‐Ciriano, I., & Bender, A. (2015) · ChemMedChem · doi:10.1002/cmdc.201500424 · Cited by 32
Systematic Quality Control Analysis of LINCS Data
Cheng, L., & Li, L. (2016) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12107 · Cited by 35
Abba, M., Abdullahi, M. E., Nor, M. H. M., Chong, C. S., & Ibrahim, Z. (2017) · IET Nanobiotechnology · doi:10.1049/iet-nbt.2017.0024 · Cited by 34
Xu, D., Liang, S., Yang, H., Bruggmann, R., Berezowska, S., Zhang, Y., Marti, T. M., Hall, S. R. R., Gao, Y., Kocher, G. J., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0724 · Cited by 34
Shan, W., Yuan, J., Hu, Z., Jiang, J., Wang, Y., Loo, N., Fan, L., Tang, Z., Zhang, T., Xu, M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107884 · Cited by 35
Self-citationKrill-Burger, J. M., Dempster, J. M., Borah, A. A., Paolella, B. R., Root, D. E., Golub, T. R., Boehm, J. S., Hahn, W. C., McFarland, J. M., Vázquez, F., et al. (2023) · Genome biology · doi:10.1186/s13059-023-03020-w · Cited by 35
Biological Networks for Cancer Candidate Biomarkers Discovery
Yan, W., Xue, W., Chen, J., & Hu, G. (2016) · Cancer Informatics · doi:10.4137/cin.s39458 · Cited by 34
Assessment of pharmacogenomic agreement
Safikhani, Z., El-Hachem, N., Quevedo, R., Smirnov, P., Goldenberg, A., Birkbak, N. J., Mason, C. E., Hatzis, C., Shi, L. M., Aerts, H. J. W. L., et al. (2016) · F1000Research · doi:10.12688/f1000research.8705.1 · Cited by 31
Preclinical Models for Bladder Cancer Research
Zhu, S., Zhu, Z. G., Ma, A., Sonpavde, G., Fan, C., & Pan, C.-X. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2021.02.007 · Cited by 33
Zhao, X., Singhal, A., Park, S., Kong, J., Bachelder, R. E., & Ideker, T. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0641 · Cited by 35
Integrative Cancer Epidemiology—The Next Generation
Spitz, M. R., Caporaso, N. E., & Sellers, T. A. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0424 · Cited by 33
Efficient and simple approach toin vitroculture of primary epithelial cancer cells
Janik, K., Popęda, M., Peciak, J., Rosiak, K., Smolarz, M., Tręda, C., Rieske, P., Stoczyńska-Fidelus, E., & Książkiewicz, M. (2016) · Bioscience Reports · doi:10.1042/bsr20160208 · Cited by 33
Sensitivity to BUB1B Inhibition Defines an Alternative Classification of Glioblastoma
Lee, E., Pain, M., Wang, H., Herman, J., Toledo, C. M., DeLuca, J. G., Yong, R. L. M., Paddison, P. J., & Zhu, J. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0736 · Cited by 32
Big Data Approaches for Modeling Response and Resistance to Cancer Drugs
Jiang, P., Sellers, W. R., & Liu, X. S. (2018) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-080917-013350 · Cited by 32
Kalu, N. N., Mazumdar, T., Peng, S., Tong, P., Shen, L., Wang, J., Banerjee, U., Myers, J. N., Pickering, C. R., Brunell, D. J., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.05.029 · Cited by 33
Making Use of Cancer Genomic Databases
Creighton, C. J. (2018) · Current Protocols in Molecular Biology · doi:10.1002/cpmb.49 · Cited by 33
Le, D., & Pham, V.-H. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.06.041 · Cited by 33
Epigenetic activation of HORMAD1 in basal-like breast cancer: role in Rucaparib sensitivity
Wang, X., Tan, Y., Cao, X., Kim, J. A., Chen, T., Hu, Y., Wexler, M., & Wang, X. (2018) · Oncotarget · doi:10.18632/oncotarget.25728 · Cited by 33
A Comprehensive Review on Deep Synergistic Drug Prediction Techniques for Cancer
Kumar, V., & Dogra, N. (2021) · Archives of Computational Methods in Engineering · doi:10.1007/s11831-021-09617-3 · Cited by 33
Genetic Susceptibility to Acute Kidney Injury
Ortega‐Loubon, C., Martínez-Paz, P., García‐Morán, E., Tamayo-Velasco, Á., López-Hernández, F. J., Jorge-Monjas, P., & Tamayo, E. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10143039 · Cited by 33
Trends in Deep Learning for Property-driven Drug Design
Born, J., & Manica, M. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210729115728 · Cited by 36
Journeys into the genome of cancer cells
Stratton, M. R. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202388 · Cited by 33
Self-citationSerine/Threonine Kinase 17A Is a Novel Candidate for Therapeutic Targeting in Glioblastoma
Mao, P., Hever-Jardine, M. P., Rahme, G. J., Yang, E. C. C., Tam, J. K. V., Kodali, A., Biswal, B. K., Fadul, C. E., Gaur, A. B., Israel, M. A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081803 · Cited by 33
Metadata
- Authors
- Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., Liu, Q., Iorio, F., Surdez, D., Chen, L., Milano, R. J., Bignell, G. R., Tam, A. T., Davies, H., Stevenson, J. A., Barthorpe, S., Lutz, S. R., Kogera, F., Lawrence, K., McLaren-Douglas, A., Mitropoulos, X., Mironenko, T., Thi, H., Richardson, L., Zhou, W., Jewitt, F., Zhang, T., O’Brien, P., Boisvert, J. L., Price, S., Hur, W., Yang, W., Deng, X., Butler, A., Choi, H. G., Chang, J. W., Baselga, J., Stamenkovic, I., Engelman, J. A., Sharma, S. V., Delattre, O., Saez-Rodriguez, J., Gray, N. S., Settleman, J., Futreal, P. A., Haber, D. A., Stratton, M. R., Ramaswamy, S., McDermott, U., & Benes, C. H.
- Affiliations
- Wellcome Sanger Institute (GB)
- Harvard University (US)
- European Bioinformatics Institute (GB)
- Institut Curie (FR)
- Centre Hospitalier Universitaire Vaudois (CH)
- Howard Hughes Medical Institute (US)
- Corresponding author
- McDermott, Ultan
- Benes, Cyril H.
- ORCID
- Garnett, Mathew J.
- Greenman, Chris D.
- Dastur, Anahita
- Lau, King Wai
- Greninger, Patricia
- Thompson, I. Richard
- Luo, Xi
- Liu, Qingsong
- Iorio, Francesco
- Surdez, Didier
- Chen, Li
- Davies, Helen
- Barthorpe, Syd
- Lawrence, Karl
- Mironenko, Tatiana
- Richardson, Laura
- Zhou, Wenjun
- Zhang, Tinghu
- O’Brien, Patrick
- Hur, Wooyoung
- Yang, Wanjuan
- Deng, Xianming
- Choi, Hwan Geun
- Chang, Jae Won
- Baselga, Jose
- Stamenkovic, Ivan
- Engelman, Jeffrey A.
- Delattre, Olivier
- Gray, Nathanael S.
- Settleman, Jeffrey
- Futreal, P. Andrew
- Haber, Daniel A.
- Stratton, Michael R.
- McDermott, Ultan
- Benes, Cyril H.
- Venue
- Nature
- Published
- 2012-03
- Volume
- 483
- Issue
- 7391
- Pages
- 570-575
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3349233
- OpenAlex
- W2125789330
- Cited by
- 2,456
- References
- 39
- Citations by year
- 2026: 106 · 2025: 101 · 2024: 114 · 2023: 145 · 2022: 161 · 2021: 228 · 2020: 162 · 2019: 183 · 2018: 212 · 2017: 198 · 2016: 214 · 2015: 199 · 2014: 197 · 2013: 153 · 2012: 82
- FWCI
- 66.78
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- SERVAL (Université de Lausanne) (acceptedVersion, other-oa)
- IRIS (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Wellcome Trust (086357)
- Cancer Research UK
- National Institutes of Health (5u54hg006097-03)
- National Human Genome Research Institute (1U54HG006097-01, U54-HG006097)
- National Institute of General Medical Sciences (P41GM079575)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- drug sensitivity, drug resistance, pharmacogenomics, cancer cell lines, genomic biomarkers, oncogene addiction, Ewing sarcoma, PARP inhibitors, topoisomerase inhibitors, SLFN11, tissue-specific biomarkers
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Cell Survival, Drug Screening Assays, Antitumor, Genetic Markers, Humans, Indoles, Neoplasms, Pharmacogenetics, Phthalazines, Piperazines, Sarcoma, Ewing, Oncogene Proteins, Fusion, Genome, Human, Gene Expression Regulation, Neoplastic, Drug Resistance, Neoplasm, Genomics, RNA-Binding Protein EWS, Cell Line, Tumor, Proto-Oncogene Protein c-fli-1, Genes, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
